Skip to main content
Premium Trial:

Request an Annual Quote

UK Government to Invest 50M in Genetics Initiative

NEW YORK, June 27 - Earlier this week, the UK government said that it plans to invest more than £50 million ($82.5 million) in genetics and genomics over the next three years.


Details of the initiative are published in a government White Paper entitled "Our Inheritance, Our Future - Realizing the potential of genetics in the NHS."


The largest part of the funding, £18 million ($29.7 million), will be used to upgrade genetics laboratories for genetic testing, and more than £7 million ($11.5 million) will go towards genetics-based healthcare.


Gene therapy research for single gene disorders will receive up to £3 million ($4.9 million), in addition to £2.5 million ($4.1 million) earmarked specifically for research into cystic fibrosis gene therapy. Moreover, £4 million ($6.6 million) will be spent on gene therapy manufacturing facilities.


Pharmacogenetics research on commonly used drugs will receive over £4 million ($6.6 million), which includes funding for a new university chair and department in pharmacogenetics.


Furthermore, the government plans to make it illegal to test someone's DNA without their consent.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.